XLRN Acceleron Pharma, Inc.
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Acceleron Pharma Inc?
What is the 52-week high for Acceleron Pharma Inc?
What is the 52-week low for Acceleron Pharma Inc?
What is Acceleron Pharma Inc stock price today?
What was Acceleron Pharma Inc stock price yesterday?
What is the PE ratio of Acceleron Pharma Inc?
What is the Price-to-Book ratio of Acceleron Pharma Inc?
What is the 50-day moving average of Acceleron Pharma Inc?